GlassScriptPhysician profile
Uma Chandavarkar
NPI 1306038096
$311.53
in general payments reported to CMS, 2019-2025
9 companies · none reported in 2025
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $116 · 2020: $23.88 · 2021: $125 · 2022: $46.37.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals LP | $171.37 | 2021-2022 | |
| Incyte Corporation | $37.24 | 2019 | |
| Puma Biotechnology, INC. | $21.01 | 2019 | |
| Genentech USA, INC. | $19.75 | 2019 | |
| Genzyme Corporation | $14.30 | 2019 | |
| Ipsen Biopharmaceuticals, INC | $12.88 | 2019 | |
| Emd Serono, INC. | $12.23 | 2020 | |
| Takeda Pharmaceuticals U.S.A., INC. | $11.65 | 2020 | |
| Novartis Pharmaceuticals Corporation | $11.10 | 2019 |
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Uma Chandavarkar listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.